COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
11 Sep 2017
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Expert commentary on melanoma immunotherapy latest
Vemurafenib for high risk melanoma patients
Dabrafenib plus trametinib for stage III mutant melanoma
Nivolumab vs ipilimumab for high risk melanoma patients
Patient perceptions of chemotherapy side effects differ over time and treatment
ABP 980, a biosimilar antibody for trastuzumab
New strategies in melanoma care
Real-world productivity of advanced gastric cancer patients
Abemaciclib for advanced breast cancer
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma